Drug Trial Radar · NCT03972657
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
345
Planned (sponsor's estimate)
Start
Aug 12, 2019
Primary completion
Nov 15, 2027
Study completion Nov 15, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors. This study is looking at several other research questions, including: 1. Side effects that may be experienced by taking REGN5678 alone or in combination with cemiplimab 2. How REGN5678 alone or in combination with cemiplimab works in the body 3. How much REGN5678 and/or cemiplimab are present in the blood 4. To see if REGN5678 alone or in combination with cemiplimab works to reduce the size of the tumor by helping the immune system destroy the tumor
Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN5678Drug
Administered as per the protocol
CemiplimabDrug
Administered as per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to 5 years
- Incidence and severity of Adverse Event of Special Interests (AESIs)Time frame: Through study completion, up to 5 years
- Incidence and severity of Serious Adverse Events (SAEs)Time frame: Through study completion, up to 5 years
- Number of participants with Grade ≥3 laboratory abnormalitiesTime frame: Through study completion, up to 5 years
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: First dose through day 42 of last participant in each dose level
- Concentration of REGN5678 in serum over timeTime frame: Through study completion, up to 5 years
- Concentration of REGN5678 in combination with cemiplimab in serum over timeTime frame: Through study completion, up to 5 years
- Composite Response Rate (CRR) of 50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic response of complete (CR) or partial response (PR)Time frame: Through study completion, up to 5 years
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaTime frame: Through study completion, up to 5 years
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Mayo Clinic
Phoenix, Arizona · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
John Wayne Cancer Institute (JWCI)
Santa Monica, California · Recruiting
Sarah Cannon Research Institute (SCRI)
Denver, Colorado · Recruiting
Yale University Hospital
New Haven, Connecticut · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Moffitt Cancer Center - McKinley Drive
Tampa, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University - The Trustees of Columbia University in the City of New York
New York, New York · Recruiting
Montefiore Medical Center
New York, New York · Recruiting
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester
Rochester, New York · Recruiting
James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Providence Portland Medical Center
Portland, Oregon · Withdrawn
Oregon Health & Science University (3485 S. Bond)
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Lifespan Cancer Institute
Providence, Rhode Island · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Emily Couric Clinical Cancer Center
Charlottesville, Virginia · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
Yonsei University - Severance Hospital - Colorectal Cancer Clinic
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea - St. Vincent's Hospital - Lung Cancer Center
Suwon, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.